This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Movement Disorders  • Parkinson Disease/ Parkinsonian Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Neurol. 2004;61:837-838.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In 2001, Freed et al¹ reported that human embryonic dopamine-neuron transplants survive in patients with severe Parkinson disease (PD) and do result in some clinical benefit in younger but not in older patients, those older than 60 years. In a similar study in 2003 with bilateral human embryonic dopamine-neuron implants in the putamen in patients with PD, Olanow et al²concluded that transplantation offered no significant improvement and could not be recommended. Both studies were unable to achieve their primary objective of major clinical improvement despite increased striatal F-18 fluorodopa uptake with positron emission tomography and data showing maintenance of transplanted neurons at postmortem examination.^1-2 Freed et al¹ did find improved motor function in a subset of patients younger than 60 years; Olanow et al did not find similar evidence but did note improvement in patients with milder disease at baseline. Of note, both studies reported disabling dyskinesia while not . . . [Full Text of this Article]

Roger N. Rosenberg, MD
Editor, Archives of Neurology

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?